Download MendeleyInhibition of Parkinson's disease-related LRRK2 by type I and type II kinase inhibitors: Activity and structures.
Sanz Murillo, M., Villagran Suarez, A., Dederer, V., Chatterjee, D., Alegrio Louro, J., Knapp, S., Mathea, S., Leschziner, A.E.(2023) Sci Adv 9: eadk6191-eadk6191
- PubMed: 38039358
- DOI: https://doi.org/10.1126/sciadv.adk6191
- Primary Citation of Related Structures:
8TXZ, 8TYQ, 8TZB, 8TZC, 8TZE, 8TZF, 8TZG, 8TZH - PubMed Abstract:
Mutations in leucine-rich repeat kinase 2 (LRRK2) are a common cause of familial Parkinson's disease (PD) and a risk factor for the sporadic form. Increased kinase activity was shown in patients with both familial and sporadic PD, making LRRK2 kinase inhibitors a major focus of drug development efforts. Although much progress has been made in understanding the structural biology of LRRK2, there are no available structures of LRRK2 inhibitor complexes. To this end, we solved cryo-electron microscopy structures of LRRK2, wild-type and PD-linked mutants, bound to the LRRK2-specific type I inhibitor MLi-2 and the broad-spectrum type II inhibitor GZD-824. Our structures revealed an active-like LRRK2 kinase in the type I inhibitor complex, and an inactive DYG-out in the type II inhibitor complex. Our structural analysis also showed how inhibitor-induced conformational changes in LRRK2 are affected by its autoinhibitory N-terminal repeats. The structures provide a template for the rational development of LRRK2 kinase inhibitors covering both canonical inhibitor binding modes.
Organizational Affiliation:
Department of Cellular and Molecular Medicine, School of Medicine, University of California San Diego, La Jolla, CA 92093, USA.
